Do analysts prefer TXMD or LEXX?

Lexaria Bioscience has a consensus price target of $22.50, suggesting a potential upside of 577.71%. Given Lexaria Bioscience's stronger consensus rating and higher probable upside, analysts plainly believe Lexaria Bioscience is more favorable than TherapeuticsMD. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score TherapeuticsMD 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Lexaria Bioscience 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Does the media favor TXMD or LEXX?

In the previous week, TherapeuticsMD had 1 more articles in the media than Lexaria Bioscience. MarketBeat recorded 4 mentions for TherapeuticsMD and 3 mentions for Lexaria Bioscience. TherapeuticsMD's average media sentiment score of 0.00 equaled Lexaria Bioscience'saverage media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment TherapeuticsMD 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Lexaria Bioscience 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend LEXX or PLRZ?

Lexaria Bioscience presently has a consensus price target of $22.50, indicating a potential upside of 577.71%. Given Lexaria Bioscience's stronger consensus rating and higher possible upside, equities analysts plainly believe Lexaria Bioscience is more favorable than Polyrizon. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lexaria Bioscience 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Polyrizon 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better earnings and valuation, LEXX or PLRZ?

Polyrizon has lower revenue, but higher earnings than Lexaria Bioscience. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Lexaria Bioscience $710K 9.87 -$11.90M -$5.10 N/A Polyrizon N/A N/A -$3.34M N/A N/A

Is LEXX or PLRZ more profitable?

Polyrizon's return on equity of 0.00% beat Lexaria Bioscience's return on equity. Company Net Margins Return on Equity Return on Assets Lexaria Bioscience N/A -174.93% -143.89% Polyrizon N/A N/A N/A

Does the media favor LEXX or PLRZ?

In the previous week, Polyrizon had 3 more articles in the media than Lexaria Bioscience. MarketBeat recorded 6 mentions for Polyrizon and 3 mentions for Lexaria Bioscience. Polyrizon's average media sentiment score of 0.58 beat Lexaria Bioscience's score of 0.00 indicating that Polyrizon is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lexaria Bioscience 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Polyrizon 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer LEXX or AYTU?

In the previous week, Aytu BioPharma had 13 more articles in the media than Lexaria Bioscience. MarketBeat recorded 16 mentions for Aytu BioPharma and 3 mentions for Lexaria Bioscience. Aytu BioPharma's average media sentiment score of 0.16 beat Lexaria Bioscience's score of 0.00 indicating that Aytu BioPharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lexaria Bioscience 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Aytu BioPharma 0 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate UPC or LEXX?

Lexaria Bioscience has a consensus price target of $22.50, indicating a potential upside of 577.71%. Given Lexaria Bioscience's stronger consensus rating and higher possible upside, analysts clearly believe Lexaria Bioscience is more favorable than Universe Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Universe Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Lexaria Bioscience 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has higher valuation and earnings, UPC or LEXX?

Universe Pharmaceuticals has higher revenue and earnings than Lexaria Bioscience. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Universe Pharmaceuticals $17.86M 1.17 -$3.67M N/A N/A Lexaria Bioscience $710K 9.87 -$11.90M -$5.10 N/A

Is UPC or LEXX more profitable?

Universe Pharmaceuticals' return on equity of 0.00% beat Lexaria Bioscience's return on equity. Company Net Margins Return on Equity Return on Assets Universe Pharmaceuticals N/A N/A N/A Lexaria Bioscience N/A -174.93% -143.89%

Does the media favor UPC or LEXX?

In the previous week, Universe Pharmaceuticals had 1 more articles in the media than Lexaria Bioscience. MarketBeat recorded 4 mentions for Universe Pharmaceuticals and 3 mentions for Lexaria Bioscience. Universe Pharmaceuticals' average media sentiment score of 0.61 beat Lexaria Bioscience's score of 0.00 indicating that Universe Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Universe Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Lexaria Bioscience 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend LEXX or COCP?

Lexaria Bioscience currently has a consensus price target of $22.50, suggesting a potential upside of 577.71%. Given Lexaria Bioscience's higher possible upside, analysts clearly believe Lexaria Bioscience is more favorable than Cocrystal Pharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lexaria Bioscience 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Cocrystal Pharma 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Is LEXX or COCP more profitable?

Lexaria Bioscience's return on equity of -174.93% beat Cocrystal Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Lexaria Bioscience N/A -174.93% -143.89% Cocrystal Pharma N/A -207.47% -123.33%

Lexaria Bioscience (LEXX) Competitors

$3.32 +0.12 (+3.75%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$3.48 +0.16 (+4.82%)

As of 10/9/2026 07:44 PM Eastern

Compare

LEXX vs. TXMD, PLRZ, AYTU, UPC, and COCP

Should you buy Lexaria Bioscience stock or one of its competitors? Lexaria Bioscience's main competitors and comparable companies include TherapeuticsMD (TXMD), Polyrizon (PLRZ), Aytu BioPharma (AYTU), Universe Pharmaceuticals (UPC), and Cocrystal Pharma (COCP). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Lexaria Bioscience compare to TherapeuticsMD?

TherapeuticsMD (NASDAQ:TXMD) and Lexaria Bioscience (NASDAQ:LEXX) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, institutional ownership, risk, earnings, analyst recommendations, dividends, media sentiment and profitability.

In the previous week, TherapeuticsMD had 1 more articles in the media than Lexaria Bioscience. MarketBeat recorded 4 mentions for TherapeuticsMD and 3 mentions for Lexaria Bioscience. TherapeuticsMD's average media sentiment score of 0.00 equaled Lexaria Bioscience'saverage media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
TherapeuticsMD	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Lexaria Bioscience	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

TherapeuticsMD has a beta of 0.65, indicating that its stock price is 35% less volatile than the broader market. Comparatively, Lexaria Bioscience has a beta of 0.61, indicating that its stock price is 39% less volatile than the broader market.

TherapeuticsMD has higher revenue and earnings than Lexaria Bioscience. Lexaria Bioscience is trading at a lower price-to-earnings ratio than TherapeuticsMD, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TherapeuticsMD	$3.02M	7.89	-$570K	$0.02	103.00
Lexaria Bioscience	$710K	9.87	-$11.90M	-$5.10	N/A

Lexaria Bioscience has a net margin of 0.00% compared to TherapeuticsMD's net margin of -6.64%. TherapeuticsMD's return on equity of -1.09% beat Lexaria Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
TherapeuticsMD	-6.64%	-1.09%	-0.78%
Lexaria Bioscience	N/A	-174.93%	-143.89%

30.7% of TherapeuticsMD shares are held by institutional investors. Comparatively, 13.1% of Lexaria Bioscience shares are held by institutional investors. 1.7% of TherapeuticsMD shares are held by company insiders. Comparatively, 8.4% of Lexaria Bioscience shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Lexaria Bioscience has a consensus price target of $22.50, suggesting a potential upside of 577.71%. Given Lexaria Bioscience's stronger consensus rating and higher probable upside, analysts plainly believe Lexaria Bioscience is more favorable than TherapeuticsMD.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TherapeuticsMD	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Lexaria Bioscience	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

TherapeuticsMD beats Lexaria Bioscience on 9 of the 15 factors compared between the two stocks.

How does Lexaria Bioscience compare to Polyrizon?

Lexaria Bioscience (NASDAQ:LEXX) and Polyrizon (NASDAQ:PLRZ) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, media sentiment, valuation, dividends, profitability, analyst recommendations, institutional ownership and risk.

In the previous week, Polyrizon had 3 more articles in the media than Lexaria Bioscience. MarketBeat recorded 6 mentions for Polyrizon and 3 mentions for Lexaria Bioscience. Polyrizon's average media sentiment score of 0.58 beat Lexaria Bioscience's score of 0.00 indicating that Polyrizon is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lexaria Bioscience	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Polyrizon	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Lexaria Bioscience has a beta of 0.61, indicating that its share price is 39% less volatile than the broader market. Comparatively, Polyrizon has a beta of -1.2, indicating that its share price is 220% less volatile than the broader market.

13.1% of Lexaria Bioscience shares are held by institutional investors. 8.4% of Lexaria Bioscience shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Polyrizon's return on equity of 0.00% beat Lexaria Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lexaria Bioscience	N/A	-174.93%	-143.89%
Polyrizon	N/A	N/A	N/A

Polyrizon has lower revenue, but higher earnings than Lexaria Bioscience.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lexaria Bioscience	$710K	9.87	-$11.90M	-$5.10	N/A
Polyrizon	N/A	N/A	-$3.34M	N/A	N/A

Lexaria Bioscience presently has a consensus price target of $22.50, indicating a potential upside of 577.71%. Given Lexaria Bioscience's stronger consensus rating and higher possible upside, equities analysts plainly believe Lexaria Bioscience is more favorable than Polyrizon.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lexaria Bioscience	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Polyrizon	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Lexaria Bioscience beats Polyrizon on 7 of the 12 factors compared between the two stocks.

How does Lexaria Bioscience compare to Aytu BioPharma?

Lexaria Bioscience (NASDAQ:LEXX) and Aytu BioPharma (NASDAQ:AYTU) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, profitability, earnings, dividends, risk, valuation and media sentiment.

Lexaria Bioscience has a beta of 0.61, meaning that its stock price is 39% less volatile than the broader market. Comparatively, Aytu BioPharma has a beta of 0.17, meaning that its stock price is 83% less volatile than the broader market.

Lexaria Bioscience has a net margin of 0.00% compared to Aytu BioPharma's net margin of -24.76%. Aytu BioPharma's return on equity of -56.54% beat Lexaria Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lexaria Bioscience	N/A	-174.93%	-143.89%
Aytu BioPharma	-24.76%	-56.54%	-13.14%

Lexaria Bioscience has higher earnings, but lower revenue than Aytu BioPharma. Aytu BioPharma is trading at a lower price-to-earnings ratio than Lexaria Bioscience, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lexaria Bioscience	$710K	9.87	-$11.90M	-$5.10	N/A
Aytu BioPharma	$57.57M	0.38	-$14.25M	-$1.66	N/A

Lexaria Bioscience currently has a consensus target price of $22.50, suggesting a potential upside of 577.71%. Aytu BioPharma has a consensus target price of $14.50, suggesting a potential upside of 614.29%. Given Aytu BioPharma's higher probable upside, analysts plainly believe Aytu BioPharma is more favorable than Lexaria Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lexaria Bioscience	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Aytu BioPharma	2 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.00

13.1% of Lexaria Bioscience shares are owned by institutional investors. Comparatively, 33.5% of Aytu BioPharma shares are owned by institutional investors. 8.4% of Lexaria Bioscience shares are owned by company insiders. Comparatively, 4.9% of Aytu BioPharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

In the previous week, Aytu BioPharma had 13 more articles in the media than Lexaria Bioscience. MarketBeat recorded 16 mentions for Aytu BioPharma and 3 mentions for Lexaria Bioscience. Aytu BioPharma's average media sentiment score of 0.16 beat Lexaria Bioscience's score of 0.00 indicating that Aytu BioPharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lexaria Bioscience	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Aytu BioPharma	0 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Aytu BioPharma beats Lexaria Bioscience on 9 of the 15 factors compared between the two stocks.

How does Lexaria Bioscience compare to Universe Pharmaceuticals?

Universe Pharmaceuticals (NASDAQ:UPC) and Lexaria Bioscience (NASDAQ:LEXX) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, earnings, valuation, media sentiment, analyst recommendations, dividends, risk and institutional ownership.

In the previous week, Universe Pharmaceuticals had 1 more articles in the media than Lexaria Bioscience. MarketBeat recorded 4 mentions for Universe Pharmaceuticals and 3 mentions for Lexaria Bioscience. Universe Pharmaceuticals' average media sentiment score of 0.61 beat Lexaria Bioscience's score of 0.00 indicating that Universe Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Universe Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Lexaria Bioscience	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

0.2% of Universe Pharmaceuticals shares are held by institutional investors. Comparatively, 13.1% of Lexaria Bioscience shares are held by institutional investors. 57.4% of Universe Pharmaceuticals shares are held by company insiders. Comparatively, 8.4% of Lexaria Bioscience shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Universe Pharmaceuticals' return on equity of 0.00% beat Lexaria Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Universe Pharmaceuticals	N/A	N/A	N/A
Lexaria Bioscience	N/A	-174.93%	-143.89%

Universe Pharmaceuticals has higher revenue and earnings than Lexaria Bioscience.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Universe Pharmaceuticals	$17.86M	1.17	-$3.67M	N/A	N/A
Lexaria Bioscience	$710K	9.87	-$11.90M	-$5.10	N/A

Lexaria Bioscience has a consensus price target of $22.50, indicating a potential upside of 577.71%. Given Lexaria Bioscience's stronger consensus rating and higher possible upside, analysts clearly believe Lexaria Bioscience is more favorable than Universe Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Universe Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Lexaria Bioscience	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Universe Pharmaceuticals has a beta of 1.68, indicating that its share price is 68% more volatile than the broader market. Comparatively, Lexaria Bioscience has a beta of 0.61, indicating that its share price is 39% less volatile than the broader market.

Summary

Universe Pharmaceuticals beats Lexaria Bioscience on 8 of the 13 factors compared between the two stocks.

How does Lexaria Bioscience compare to Cocrystal Pharma?

Lexaria Bioscience (NASDAQ:LEXX) and Cocrystal Pharma (NASDAQ:COCP) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, profitability, earnings, analyst recommendations, media sentiment, institutional ownership, dividends and valuation.

Lexaria Bioscience's return on equity of -174.93% beat Cocrystal Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lexaria Bioscience	N/A	-174.93%	-143.89%
Cocrystal Pharma	N/A	-207.47%	-123.33%

Lexaria Bioscience currently has a consensus price target of $22.50, suggesting a potential upside of 577.71%. Given Lexaria Bioscience's higher possible upside, analysts clearly believe Lexaria Bioscience is more favorable than Cocrystal Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lexaria Bioscience	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Cocrystal Pharma	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

13.1% of Lexaria Bioscience shares are owned by institutional investors. Comparatively, 6.7% of Cocrystal Pharma shares are owned by institutional investors. 8.4% of Lexaria Bioscience shares are owned by company insiders. Comparatively, 39.4% of Cocrystal Pharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

In the previous week, Lexaria Bioscience had 1 more articles in the media than Cocrystal Pharma. MarketBeat recorded 3 mentions for Lexaria Bioscience and 2 mentions for Cocrystal Pharma. Lexaria Bioscience's average media sentiment score of 0.00 equaled Cocrystal Pharma'saverage media sentiment score.

Company	Overall Sentiment
Lexaria Bioscience	Neutral
Cocrystal Pharma	Neutral

Lexaria Bioscience has a beta of 0.61, meaning that its share price is 39% less volatile than the broader market. Comparatively, Cocrystal Pharma has a beta of 1.48, meaning that its share price is 48% more volatile than the broader market.

Cocrystal Pharma has lower revenue, but higher earnings than Lexaria Bioscience. Cocrystal Pharma is trading at a lower price-to-earnings ratio than Lexaria Bioscience, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lexaria Bioscience	$710K	9.87	-$11.90M	-$5.10	N/A
Cocrystal Pharma	N/A	N/A	-$8.83M	-$0.76	N/A

Summary

Lexaria Bioscience beats Cocrystal Pharma on 6 of the 11 factors compared between the two stocks.

Get Lexaria Bioscience News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LEXX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

LEXX vs. The Competition

Export

Metric	Lexaria Bioscience	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$6.74M	$12.31B	$7.16B	$13.21B
Dividend Yield	N/A	2.64%	2.53%	16.37%
P/E Ratio	-0.65	797.58	275.02	26.16
Price / Sales	9.87	939.75	635.97	107.44
Price / Cash	N/A	85.97	76.38	53.09
Price / Book	1.66	10.71	11.22	6.33
Net Income	-$11.90M	$2.84B	$3.50B	$382.15M
7 Day Performance	15.28%	-0.94%	-0.89%	-1.40%
1 Month Performance	-18.02%	-4.89%	-4.42%	-3.47%
1 Year Performance	-74.16%	-4.12%	7.03%	1.18%

Lexaria Bioscience Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
LEXX Lexaria Bioscience	1.4929 of 5 stars	$3.32 +3.8%	$22.50 +577.7%	-75.2%	$6.74M	$710K	N/A	7	News Coverage Analyst Upgrade Gap Up High Trading Volume
TXMD TherapeuticsMD	1.0108 of 5 stars	$2.02 +0.5%	N/A	+94.3%	$23.26M	$3.02M	101.00	420	News Coverage
PLRZ Polyrizon	1.2049 of 5 stars	$9.67 +4.4%	N/A	+19.9%	$22.49M	N/A	N/A	1	Analyst Downgrade Gap Down
AYTU Aytu BioPharma	2.9288 of 5 stars	$2.05 +0.5%	$14.50 +607.3%	-19.1%	$22.17M	$57.57M	N/A	83	Analyst Downgrade Analyst Revision
UPC Universe Pharmaceuticals	1.0696 of 5 stars	$4.21 -3.0%	N/A	-42.5%	$21.81M	$17.86M	N/A	216	News Coverage Short Interest Decrease Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:LEXX) was last updated on 10/10/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Lexaria Bioscience (LEXX) Competitors

LEXX vs. TXMD, PLRZ, AYTU, UPC, and COCP

How does Lexaria Bioscience compare to TherapeuticsMD?

Summary

How does Lexaria Bioscience compare to Polyrizon?

Summary

How does Lexaria Bioscience compare to Aytu BioPharma?

Summary

How does Lexaria Bioscience compare to Universe Pharmaceuticals?

Summary

How does Lexaria Bioscience compare to Cocrystal Pharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LEXX vs. The Competition

Lexaria Bioscience Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Lexaria Bioscience (LEXX) Competitors

LEXX vs. TXMD, PLRZ, AYTU, UPC, and COCP

How does Lexaria Bioscience compare to TherapeuticsMD?

Does the media favor TXMD or LEXX?

Which has more volatility and risk, TXMD or LEXX?

Which has better earnings & valuation, TXMD or LEXX?

Is TXMD or LEXX more profitable?

Do insiders & institutionals have more ownership in TXMD or LEXX?

Do analysts prefer TXMD or LEXX?

Summary

How does Lexaria Bioscience compare to Polyrizon?

Does the media favor LEXX or PLRZ?

Which has more risk and volatility, LEXX or PLRZ?

Do insiders and institutionals believe in LEXX or PLRZ?

Is LEXX or PLRZ more profitable?

Which has better earnings and valuation, LEXX or PLRZ?

Do analysts recommend LEXX or PLRZ?

Summary

How does Lexaria Bioscience compare to Aytu BioPharma?

Which has more volatility & risk, LEXX or AYTU?

Is LEXX or AYTU more profitable?

Which has stronger earnings & valuation, LEXX or AYTU?

Do analysts recommend LEXX or AYTU?

Do insiders & institutionals hold more shares of LEXX or AYTU?

Does the media prefer LEXX or AYTU?

Summary

How does Lexaria Bioscience compare to Universe Pharmaceuticals?

Does the media favor UPC or LEXX?

Do insiders and institutionals have more ownership in UPC or LEXX?

Is UPC or LEXX more profitable?

Which has higher valuation and earnings, UPC or LEXX?

Do analysts rate UPC or LEXX?

Which has more risk & volatility, UPC or LEXX?

Summary

How does Lexaria Bioscience compare to Cocrystal Pharma?

Is LEXX or COCP more profitable?

Do analysts recommend LEXX or COCP?

Do institutionals & insiders hold more shares of LEXX or COCP?

Does the media favor LEXX or COCP?

Which has more volatility & risk, LEXX or COCP?

Which has preferable earnings & valuation, LEXX or COCP?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LEXX vs. The Competition

Lexaria Bioscience Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools